Mylan Inks $264M Deal Ending EpiPen Class Price-Hike Suit

By Bonnie Eslinger · February 28, 2022, 9:19 PM EST

Health care company Viatris — formerly known as Mylan — said Monday that it has agreed to a $264 million settlement to resolve class action claims that it conspired with Pfizer Inc....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Bonnie

November 05, 2024
Eye-Rolling Must Stop, Judge Warns Before False Ad Trial
October 11, 2024
9th Circ. Backs Planned Parenthood's $14M Atty Fee Win
October 03, 2024
Texas Transgender Health Rule Suit Paused For Gov't Appeal
October 02, 2024
Lab Co. Settles Bogus Testing Claims With Feds For $27M
August 28, 2024
Del. Justices OK Mid-Case Appeal In Zantac Class Suit
August 16, 2024
States Get Teva Generic Price-Fix Case On Docket As 1st Trial
August 09, 2024
DC Circ. Pans Suit Claiming HHS Caused Health Aid Shortage
June 28, 2024
Texas Justices Back Ban On Gender Affirming Care For Minors
June 28, 2024
Jury Convicts Seattle Doctor In NBA Health Fraud Case
May 17, 2024
Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca